EMEA-002551-PIP01-18 - paediatric investigation plan

capivasertib

Key facts

• Active substance:
  capivasertib
• Therapeutic area:
  Oncology
• Decision number:
  P/0214/2019
• PIP number:
  EMEA-002551-PIP01-18
• Pharmaceutical form(s):
  Film-coated tablet
• Condition(s) / indication(s):
  • Treatment of breast cancer
  • Treatment of prostate cancer
• Route(s) of administration:
  Oral use
• Decision type:
  W: decision granting a waiver in all age groups for all conditions or indications
• Decision date:
  12/06/2019
• Compliance check done:
  No

Decision

P/0214/2019: EMA decision of 12 June 2019 on the granting of a product specific waiver for capivasertib (EMEA-002551-PIP01-18)

Adopted Reference Number: EMA/289392/2019